Evidence map›Paper›PMID 40271486›Full record

ArticleFrontiers in veterinary science2025

CD86 is linked to apoptosis in canine histiocytic sarcoma.

Benjamin Diehl, Andreas Kirchhoff, Florian Hansmann

Abstract read
In one paragraph

Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Benjamin DiehlFaculty of Veterinary Medicine, Institute of Veterinary Pathology, Leipzig University, Leipzig, Germany.
Andreas KirchhoffPractice of Veterinary Pathology, Gelsenkirchen, Germany.
Florian HansmannFaculty of Veterinary Medicine, Institute of Veterinary Pathology, Leipzig University, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoints are critical for the regulation of tumor growth and regression. Recently an effect of CD80 and CD86 on tumor regression in canine cutaneous histiocytoma has been described. Further, the expression of MX dynamin like GTPase 1 (mx1) in cancer is linked to immune evasion. Thus, the present study aimed to investigate the effects of CD80 and CD86 in histiocytic sarcoma (HS), a rare and progressive malignancy in dogs and to elucidate the status of the interferon-I pathway. Twenty-two tissue samples of HS from skin, lung and liver of 15 dogs were used. Immunohistochemistry targeting CD80, CD86, programmed death-ligand 1 (PD-L1), survivin, cleaved caspase-3 (Casp-3), stimulator of interferon genes (STING) and mx1 was performed. Slides were digitized and analyzed with QuPath. The numbers of CD86- and Casp-3 expressing cells showed a positive correlation. In the skin and lung, numbers of CD80 immunolabeled cells were higher than for CD86, while CD80 and CD86 levels were comparable in the liver. In general, low numbers of PD-L1 immunolabeled tumor cells were detected. Intranuclear survivin expression was linked to Casp-3. Mx1 and STING were expressed in tumor cells. A possible link between CD86 and Casp-3 points to a role of CD86 in tumor cell death. The findings indicate relevant differences in CD80 and CD86 expression between organs and a function in histiocytic disease in dogs. Further, the expression of markers of the interferon-type-I pathway indicates a role in immune evasion.

Indexed as

CD80CD86doghistiocytic sarcomaimmune checkpointmx1survivin

Identifiers

PMID40271486
PMCPMC12014657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.